Accretion Nutraveda
LISTEDIPO Date: 28 Jan - 30 Jan 2026
Listing Date: 4 Feb 2026
Price Range
Rs.122 - Rs.129
Issue Size
25 Cr
Min Investment
₹2,44,000
2 lots minimum (SEBI rule for SME)
Min Application
2000 Shares
1000 per lot × 2
Schedule of Accretion Nutraveda
Issue open date
28 Jan 2026
Issue close date
30 Jan 2026
UPI mandate deadline
30 Jan 2026 (5 PM)
Allotment finalization
2 Feb 2026
Share credit
3 Feb 2026
Listing date
4 Feb 2026
Mandate end date
14 Feb 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 25 Cr |
| Fresh Issue | 24.77 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 2 Feb 2026 |
| Allotment Link | {Link} |
Grey Market Premium
NewGrey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | IPO Price | GMP | Est. Listing Price |
|---|---|---|---|
| 3 Feb 2026Latest | ₹129 | ₹68 | ₹197(+52.71%) |
| 1 Feb 2026 | ₹129 | ₹6 | ₹135(+4.65%) |
| 31 Jan 2026 | ₹129 | ₹6 | ₹135(+4.65%) |
| 29 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 27 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 26 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 25 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 24 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 23 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 22 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 21 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
| 20 Jan 2026 | ₹129 | ₹0 | ₹129(0%) |
Performance Accretion Nutraveda
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.122 - Rs.129 | ₹ 191 (48.06%) | ₹ 272.2 | 111.01% |
About Accretion Nutraveda
Accretion Nutraveda Limited manufactures Ayurvedic and nutraceutical products and functions as a contract development and manufacturing organisation, serving domestic and export markets. It makes tablets, capsules, oral liquids, oral powders, external preparations, and oils. Tablets include film-coated and chewable varieties used in liver care, gynaecological care, bone and joint health, and respiratory support. Capsules include hard gelatin and HPMC formats for liver detoxification, women’s health, and cognitive support. Oral liquids include syrups, suspensions, and tonics for paediatric and geriatric use. It also produces churan powders, medicated Ayurvedic oils, and external balms, ointments, creams, and gels for pain relief, skin care, and hair care. The company runs a leased, two-floor manufacturing facility with 13 HEPA-filter air handling units and segregated processing and dispensing areas to limit cross-contamination.
| Founded in | 2021 |
| Managing director | Mr Mayur Popatlal Sojitra |
| Parent organization |
Financial Overview
Strengths
5- 1
Diverse Ayurvedic and nutraceutical dosage capabilities under one facility
- 2
Strong CDMO focus with repeat domestic and export clients
- 3
Multiple quality certifications, including WHO-GMP, FSSC 22000 and ISO
- 4
Experienced promoter-led management with hands-on operations control
- 5
Consistent revenue and profitability growth over recent years
Risks
5- 1
High revenue dependence on the domestic and merchant export segment
- 2
The manufacturing facility is leased, not owned
- 3
Business exposed to regulatory changes in the Ayurveda and nutraceutical space
- 4
Dependence on a limited number of key customers
- 5
Geographic revenue concentration is largely within Gujarat
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 1.01 |
| Non-Institutional Investors (NIIs) | 1.8 |
| Retail Individual Investors (RIIs) | 2.19 |
| Employee | N/A |
| Total | 1.77 |